Hematopoietic System--Cancer clinical trials at UCSF
1 research study open to eligible people
The hematopoietic system--cancer is when cancer cells grow in the blood-forming tissues of the body. UCSF is conducting a clinical trial to study a medication called olanzapine for controlling nausea and vomiting in children who receive chemotherapy that causes these symptoms. The goal is to help reduce discomfort during cancer treatment.
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
open to eligible people ages 30 months to 18 years
Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy
San Francisco, California and other locations
Our lead scientists for Hematopoietic System--Cancer research studies include Christopher Dvorak.